Evidence map›Paper›PMID 37151423›Full record

ArticleClinical kidney journal2023

A small circulating miRNAs signature predicts mortality and adverse cardiovascular outcomes in chronic hemodialysis patients.

Davide Bolignano, Marta Greco, Pierangela Presta, Anila Duni, Caterina Vita, Ethymios Pappas, Maria Mirabelli, Lampros Lakkas, Katerina K Naka, Antonio Brunetti and 4 more

Abstract read
In one paragraph

Article in Clinical kidney journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Roles of microRNAs in cardiorenal syndrome.Molecular and cellular biochemistry · 2025
    Review
  4. Observational
  5. Article
  6. Article
  7. Review
  8. miRNAs in Uremic Cardiomyopathy: A Comprehensive Review.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Davide BolignanoMagna Graecia University, Nephrology and Dialysis Unit, Catanzaro, Italy.ORCID https://orcid.org/0000-0003-3032-245X
Marta GrecoMagna Graecia University, Department of Health Sciences, Catanzaro, Italy.
Pierangela PrestaMagna Graecia University, Nephrology and Dialysis Unit, Catanzaro, Italy.
Anila DuniDepartment of Nephrology, School of Medicine, University of Ioannina, Ioannina, Greece.
Caterina VitaMagna Graecia University, Nephrology and Dialysis Unit, Catanzaro, Italy.
Ethymios PappasHemodialysis Unit, General Hospital of Filiates, Filiates, Greece.
Maria MirabelliMagna Graecia University, Department of Health Sciences, Catanzaro, Italy.
Lampros LakkasSecond Department of Cardiology, University Hospital of Ioannina, Ioannina, Greece.
Katerina K NakaSecond Department of Cardiology, University Hospital of Ioannina, Ioannina, Greece.
Antonio BrunettiMagna Graecia University, Department of Health Sciences, Catanzaro, Italy.
Daniela Patrizia FotiMagna Graecia University, Experimental and Clinical Medicine, Catanzaro, Italy.
Michele AndreucciMagna Graecia University, Nephrology and Dialysis Unit, Catanzaro, Italy.
Giuseppe CoppolinoMagna Graecia University, Nephrology and Dialysis Unit, Catanzaro, Italy.
Evangelia DounousiDepartment of Nephrology, School of Medicine, University of Ioannina, Ioannina, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chronic hemodialysis (HD) patients exhibit severe morpho-functional cardiac alterations, putting them at a high risk of death and adverse cardiovascular (CV) outcomes. Despite the fact that an unbalanced expression of various microRNAs (miRNAs) has been related to pathological cardiac remodeling and worse CV outcomes, scarce evidence exists on their role in this setting. Methods: We evaluated circulating levels of a selected miRNAs panel (30a-5p, 23a-3p, 451a and let7d-5p) in 74 chronic HD patients together with a thorough clinical and echocardiography assessment. Individuals were then prospectively followed (median 22 months). The primary endpoint was a composite of all-cause and CV mortality and non-fatal CV events. Results: Circulating levels of all miRNAs were lower in HD patients as compared with healthy controls and independently correlated to the severity of cardiac dysfunction. miRNA 30a-5p, 23a-3p and 451a expression was even lower in 30 subjects (40.5%) reaching the composite endpoint ( Conclusions: Lower circulating levels of miRNA 30-5p, 23a-3p and 451a in HD patients may reflect cardiac abnormalities and predict a higher risk of worse clinical outcomes in the short mid-term. Future studies on larger HD populations are needed to generalize these findings.

Indexed as

cardiovascular eventshemodialysismiRNAmortality

Identifiers

PMID37151423
PMCPMC10157794

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.